ABSTRACT
Objective@#To observe the clinical effect of self-made Jiuxin decoction in the treatment of end-stage hypertrophic non-obstructive cardiomyopathy.@*Methods@#From July 2016 to October 2017, 60 patients with end-stage hypertrophic non-obstructive cardiomyopathy in the First People′s Hospital of Yuhang District were randomly divided into two groups according to digital table, with 30 cases in each group.The control group was treated with conventional western medicine, and the observation group was treated with self-made Jiuxin soup for a week.The changes of body weight, degree of edema, NYHA class, Lee score, B-type natriuretic peptide, blood angiotensin Ⅱ, blood potassium, sodium, chlorine content and other indicators before and after treatment were observed in the two groups.@*Results@#After one-week treatment, the cardiac function and heart failure indicators of the two groups were all significantly improved(the observation group: t=10.527, 15.358, all P<0.01; the control group: t=7.504, 12.417, all P<0.01), and the indicators of the observation group were better than those of the control group, and the differences between the two groups were statistically significant(t=3.772, 4.446, all P<0.01). After treatment, the levels of B-type natriuretic peptide of the two groups were significantly lower than those before treatment (the observation group: t=5.628, the control group: t=11.423, all P<0.05). The angiotensin and renin levels in the observation group were all significantly lower than those before treatment(t=4.355, 6.418, all P<0.05), and the indicators of the observation group were all significantly lower than those of the control group(t=3.521, 4.275, all P<0.05). The incidence rate of adverse reaction of the observation group was significantly lower than that of the control group(3.3% vs.23.3%, χ2=5.192, P=0.023).@*Conclusion@#Self-made Jiuxin decoction can significantly improve the cardiac function in patients with end-stage hypertrophic non-obstructive cardiomyopathy and it is a safe way of treatment.
ABSTRACT
Objective To investigate the effects of irbesartan hydrochlorothiazide combined with candesartan cilexetil in the treatment of elderly patients with hypertension and its protective effect on cardiac function.Methods 180 elderly patients with hypertension were selected,and they were randomly divided into observation group and control group according to the digital table,90 cases in each group.The observation group was given irbesartan hydrochlorothiazide combined with candesartan treatment,the control group was given candesartan.The heart function improvement after treatment,clinical efficacy and patients in hospitalization,complications,critical events and new death of the two groups were compared.Results After treatment,the heart rate,EVDD,SBP and other indicators of the two groups declined,which of the observation group[(56.14 ± 6.15)mm,(112.12 ± 20.12)mmHg,(70.45 ± 8.69/min)]were lower than the control group[(60.12 ± 6.78) mm(119.45 ± 21.45) mmHg,(82.12 ± 9.12/ min)],there were significant differences between the two groups (t1 =4.124,P =0.000;t2 =2.364,P =0.019;t3 =8.788,P =0.000).The total effective rate of the observation group was 93.33％,which was higher than 74.44％ of the control group,there was significant difference between the two groups (x2 =11.879,P =0.000).Conclusion Irbesartan hydrochlorothiazide combined with candesartan in the treatment of elderly hypertensive patients can effectively improve the heart function of patients,has significant effect.
ABSTRACT
Objective To analyze and investigate dopamine combined with milrinone treatment effect on elderly patients with intractable heart failure and N-terminal B-type natriuretic peptide level and cardiac function.Methods 80 cases of elderly patients with heart failure according to the number table method randomly divided into two groups: control group and experimental group, and control group was given conventional drugs.The patients in experimental group were received dopamine +Milrinone on the basis of control group.Clinical efficacy, N-terminal pro-B-type natriuretic peptide levels ( NT proBNP ) and heart function condition between two groups are compared and analyzed.Results The total effective rate of experimental group (95.00%) was higher than that of control group (70.00%) (P<0.05).NT-proBNP(2013.31 ±295.84)ng/L、LVEDD(61.48 ± 10.11)mm、LVEF(59.69 ±8.44)% in the experimental group was significantly better than the control group(P <0.05).Conclusion Dopamine combined with milrinone in the treatment of elderly patients with intractable heart failure is remarkable, can relieve the level of NT proBNP, and promote the recovery of cardiac function.
ABSTRACT
Objective To explore the therapeutic efficacy of irbesartan combined amlodipine for the treatment of hypertension and diabetic nephropathy.Methods 120 patients with diabetic nephropathy and hypertension received from March 2011 to March 2014 were randomly divided into three groups according to its administration circumstances ( irbesartan group and amlodipine group, irbesartan and amlodipine groups) , with 40 patients in each group.Blood pressure, 24h urine albumin, 24h urinary protein excretion and urine β2-microglobulin and other indicators of the three groups of patients were observed and compared after 10 weeks of treatment.Results After treatment, the total efficiency of A, B two groups was no significant difference.The total effective rate of group C (92.5%) was significantly higher than that in A group (χ2 =6.65, P<0.05), the total effective rate of group C was significantly higher than that of group B (χ2 =7.81, P<0.05).The blood pressure in patients of three groups were all dropped to normal after treatment, but the one in combination group was significantly lower than the irbesartan group and amlodipine group, the difference was statistically significant (P<0.05).The urine tests related indicators of patients in the three groups were also significantly reduced after treatment , but 24 h urine albumin, 24 h urinary protein excretion and urine β2-microglobulin in combination group were significantly lower than the irbesartan group and amlodipine group, the difference was statistically significant (P<0.05).Three groups were no obvious adverse reactions. Conclusion Irbesartan combined amlodipine for the treatment of hypertension and diabetic nephropathy has significant efficacy compared to single drug.